胸主动脉腔内修复术中原位激光开窗治疗急性和亚急性主动脉弓疾病的早中期结果及并发症分析
回顾性分析2017年1月至2019年3月148例接受TEVAR联合原位激光开窗(ISLF)治疗急/亚急性复杂主动脉弓疾病患者(共183支弓上血管),技术成功率97.3%,30天死亡率2.9%,随访平均15个月死亡率3.4%。并发症包括内漏7例(4.7%)、逆行夹层3例(2.0%)、卒中5例(3.4%),无分支支架闭塞或脊髓缺血。多血管开窗并发症更多,且TAAD并发症率显著高于TBAD(P=.008)。
要点
- ISLF在TEVAR中治疗急/亚急性复杂弓部疾病早中期安全有效,技术成功率97.3%。
- 多血管激光开窗并发症更多,TAAD行多血管开窗需谨慎。
- TAAD并发症率显著高于TBAD(P=.008),应审慎干预。
核心结论
- 基于大样本早中期随访,TEVAR联合ISLF治疗近端主动脉弓急/亚急性复杂疾病安全有效。
- 对TAAD采用TEVAR辅助多血管激光开窗时应谨慎。
- 需继续研究以阐明该微创治疗在紧急情况下的长期结果。
研究设计与样本
- 单中心回顾性分析前瞻性收集的数据,时间2017年1月至2019年3月。
- 共148例患者(105男、43女),年龄21~79岁(平均54.9±12.9岁),共183支弓上血管。
- 症状发作至手术时间平均7±3天;存活者随访5~24个月(平均15±5个月)。
- 单血管开窗124例,双血管开窗13例,三血管开窗11例。
主要发现
- 技术失败4例,技术成功率97.3%。
- 术后内漏7例(4.7%):1例IB型(左锁骨下动脉分支支架远端)、3例IIIC型(开窗部位)、3例II型。
- 逆行夹层3例(2.0%),卒中5例(3.4%)。
- 30天死亡3例(30天死亡率2.9%),随访平均15个月死亡2例(死亡率3.4%)。
- 术后及随访期间无分支支架闭塞或脊髓缺血;弓部疾病分布随开窗血管数量显著不同(P<.001),TAAD更可能接受多血管开窗,TBAD更可能接受单血管开窗;并发症率在不同弓部疾病间差异显著,TAAD高于TBAD(P=.008)。
临床怎么用
- 对于急/亚急性复杂主动脉弓疾病,TEVAR联合ISLF可作为近端弓部治疗选择。
- TAAD需多血管激光开窗时并发症风险较高,应谨慎选择。
- 术后需关注内漏、逆行夹层和卒中,随访中无分支支架闭塞或脊髓缺血。
局限性
- 回顾性设计,单中心经验。
- 随访时间有限(平均15个月),长期结果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An analysis was conducted of early and midterm outcomes of a large series of patients treated with in situ laser fenestration (ISLF) during thoracic endovascular aortic repair (TEVAR) of acute and subacute complex aortic arch diseases, such as Stanford type A aortic dissection (TAAD), type B aortic dissection (TBAD) requiring proximal sealing at zone 2 or more proximal, thoracic aortic aneurysm or pseudoaneurysm, and penetrating aortic ulcer. We present the perioperative and follow-up outcomes and discuss the rate of complications. METHODS: This is a retrospective review of prospectively collected data from January 2017 to March 2019 of patients treated with TEVAR and ISLF of aortic arch branches at a large tertiary academic institution in an urban city in China. Preoperative, intraoperative, and follow-up clinical and radiographic data are analyzed and discussed. RESULTS: A total of 148 patients presented with symptomatic and acute or subacute TAAD, TBAD, thoracic aortic aneurysm, or penetrating aortic ulcer for a total of 183 arch vessels. There were 105 men and 43 women, 21 to 79 years of age (mean, 54.9 ± 12.9 years). Time from symptom onset to time of surgery was an average of 7 ± 3 days. Survivor follow-up duration ranged from 5 to 24 months (mean, 15 ± 5 months). Single-vessel fenestration was carried out in 124 cases, two-vessel fenestration in 13 cases, and three-vessel fenestration in 11 cases. There were four cases with technical failure to laser fenestration, with a technical success rate of 97.3%. Postoperatively, there were seven cases of endoleak (4.7%; one type IB distal from the left subclavian artery branch stent graft, three type IIIC at the fenestration site, and three type II), three retrograde dissections (2.0%), and five strokes (3.4%); death occurred in three patients with 30-day mortality of 2.9%, and two deaths occurred during follow-up for 3.4% mortality at an average 15 months of follow-up. There was no branch stent graft occlusion or spinal ischemia postoperatively or during follow-up. The distribution of arch diseases varied significantly according to the number of vessels that were laser fenestrated; TAAD was more likely to receive multivessel laser fenestrations, and TBAD was more likely to receive single-vessel fenestration (P < .001). The rate of complications was distributed differently between the three ISLF groups, with more complications occurring in multivessel fenestrations. However, a statistical weakening was observed when frequency of complications between the three groups was stratified by type of arch disease. The complication rate varied significantly between the different arch diseases, higher in TAAD than in TBAD (P = .008). CONCLUSIONS: ISLF during TEVAR for treatment of acute and subacute complex aortic arch diseases in the proximal aortic arch is safe and effective on the basis of these early to midterm follow-up data of a large cohort. However, care should be taken in intervening on TAAD using TEVAR with adjunctive multivessel laser fenestration. Continued investigation of TEVAR and adjunctive ISLF is needed to elucidate the long-term outcomes of this minimally invasive treatment for complex aortic arch disease in an urgent setting.
引用
- Li C, Xu P, Hua Z, et al. Early and midterm outcomes of in situ laser fenestration during thoracic endovascular aortic repair for acute and subacute aortic arch diseases and analysis of its complications. J Vasc Surg. 2020. PMID: 32273224. doi:10.1016/j.jvs.2020.01.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。